ALBI分级在临床应用的现状及进展

Current Status and Progress of Clinical Application of ALBI Classification

白蛋白–胆红素(ALBI)评分是近年来新出现的评价肝细胞癌(HCC)患者肝功能情况的模型,可以良好评价患者肝功能及预后。本文主要介绍ALBI分级在HCC,病毒性肝炎、肝硬化、胃癌、非小细胞肺癌等方面的应用现状以及ALBI分级的新分期新模型,认为ALBI分级不仅局限于HCC的应用而且与现有其他模型相比具有一定优势。

Albumin-bilirubin (ALBI) score is a newly emerged model for evaluating liver function in patients with hepatocellular carcinoma (HCC) in recent years, which can well evaluate liver function and prognosis of patients. This article mainly focuses on the application status of ALBI grading in HCC, viral hepatitis, liver cirrhosis, gastric cancer, non-small cell lung cancer, and the new staging model of ALBI grading. It is believed that ALBI grading is not only limited to the application of HCC, but al-so has certain advantages compared with other existing models.